Corvia Medical

Corvia Medical is a pioneering private medical device company developing the Corvia Atrial Shunt, the world's first atrial shunt therapy aimed at transforming treatment for heart failure (HF) with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF). Its device is designed to create a small, permanent passage between the left and right atria to decompress the left heart, addressing the high pressures that drive HF symptoms and hospitalizations. The company's progress is supported by data from the extensive REDUCE LAP-HF II trial and the ongoing RESPONDER-HF study, positioning it as a leader in the emerging field of device-based HF interventional therapies. Corvia operates globally but its device remains investigational in the United States.

Percutaneous interatrial shunt device designed to reduce left atrial pressure in heart failure by creating a permanent passage between the left and right atria.

Corvia is a first-mover in a nascent but competitive field. Direct competitors include V-Wave (interatrial shunt) and Edwards Lifesciences (investigational shunt device). The landscape also includes pharmaceutical SGLT2 inhibitors for HFpEF and other device-based approaches targeting different mechanisms, such as baroreflex activation and cardiac contractility modulation.